ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E0.11 EPS (ttm)6.21 Insider Own0.30% Shs Outstand7.38M Perf Week-2.76%
Market Cap5.40M Forward P/E- EPS next Y-2.93 Insider Trans0.00% Shs Float7.36M Perf Month-46.97%
Income47.00M PEG- EPS next Q-0.51 Inst Own12.40% Short Float / Ratio9.43% / 2.85 Perf Quarter-64.65%
Sales1.50M P/S3.60 EPS this Y38.20% Inst Trans6.34% Short Interest0.69M Perf Half Y-83.88%
Book/sh3.69 P/B0.19 EPS next Y-142.20% ROA72.70% Target Price80.00 Perf Year-87.47%
Cash/sh2.06 P/C0.34 EPS next 5Y- ROE- 52W Range0.57 - 7.60 Perf YTD-69.03%
Dividend- P/FCF- EPS past 5Y21.00% ROI162.80% 52W High-90.79% Beta0.36
Dividend %- Quick Ratio1.50 Sales past 5Y-30.50% Gross Margin- 52W Low23.09% ATR0.12
Employees43 Current Ratio1.60 Sales Q/Q-73.70% Oper. Margin- RSI (14)28.30 Volatility12.82% 15.31%
OptionableYes Debt/Eq0.29 EPS Q/Q33.10% Profit Margin- Rel Volume1.50 Prev Close0.72
ShortableYes LT Debt/Eq0.00 EarningsMar 30 AMC Payout0.00% Avg Volume243.73K Price0.70
Recom2.50 SMA20-23.24% SMA50-52.29% SMA200-78.87% Volume362,864 Change-2.78%
Jul-20-20Downgrade Credit Suisse Neutral → Underperform
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Show Previous Ratings
Mar-30-23 06:15PM
04:05PM
Mar-29-23 10:13AM
Mar-21-23 04:05PM
Mar-14-23 08:30AM
08:30AM Loading…
Mar-01-23 08:30AM
Dec-29-22 06:02AM
Dec-27-22 08:30AM
Dec-19-22 08:17AM
Dec-08-22 08:30AM
Nov-17-22 05:17AM
Nov-14-22 05:15PM
04:01PM
Nov-03-22 08:30AM
Oct-31-22 08:30AM
08:30AM Loading…
Oct-27-22 08:30AM
Oct-26-22 08:30AM
Oct-25-22 04:42PM
08:30AM
Sep-06-22 04:30PM
Aug-25-22 08:30AM
Aug-11-22 05:35PM
04:01PM
08:30AM
Aug-10-22 08:30AM
Jul-28-22 04:50PM
Jul-08-22 06:28AM
May-20-22 12:49PM
May-19-22 11:56AM
08:30AM
08:45AM Loading…
May-16-22 08:45AM
07:30AM
May-12-22 05:35PM
May-10-22 05:35PM
08:30AM
May-09-22 07:30PM
Apr-27-22 08:00AM
Apr-25-22 08:30AM
Apr-21-22 08:30AM
Mar-31-22 04:10PM
Mar-29-22 01:08PM
Mar-10-22 05:15PM
04:01PM
Mar-03-22 04:05PM
Feb-01-22 08:30AM
Jan-31-22 04:24AM
Jan-27-22 01:38PM
08:30AM
Jan-12-22 08:30AM
Jan-10-22 08:30AM
Dec-23-21 08:05AM
Dec-15-21 08:30AM
Dec-01-21 07:12PM
Nov-23-21 05:09PM
Nov-15-21 06:45AM
06:00AM
Nov-10-21 08:30AM
Nov-02-21 06:22AM
Oct-28-21 03:06PM
Oct-21-21 09:32PM
Oct-04-21 07:30AM
Sep-10-21 03:19PM
Aug-30-21 05:10PM
08:30AM
Aug-26-21 08:30AM
Aug-19-21 07:07AM
Aug-16-21 05:25PM
04:01PM
Aug-12-21 04:01PM
Aug-09-21 04:30PM
01:30PM
10:16AM
10:00AM
09:25AM
08:30AM
12:20AM
Aug-08-21 01:00PM
Aug-07-21 02:35PM
Aug-06-21 09:33PM
07:15PM
02:30PM
01:03PM
01:00PM
12:15PM
10:00AM
Aug-05-21 11:25AM
Aug-04-21 08:00PM
12:00PM
11:20AM
11:05AM
10:00AM
01:17AM
Aug-03-21 10:45PM
12:00PM
11:18AM
Aug-02-21 10:24PM
03:01PM
01:05PM
12:30PM
11:00AM
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angotti Vincent J.Chief Executive OfficerJun 07Buy0.2246,40010,3331,016,919Jun 08 04:06 PM